Functional antagonism of the caffeine-discriminative stimulus by triazolam in humans

Behavioural Pharmacology

Volumn 8, Issue 2-3, 1997, Pages 124-138

  Oliveto, A H ^a,b   Bickel, W K ^a   Hughes, J R ^a   Higgins, S T ^a   Badger, G ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Antagonism; Buspirone; Caffeine; Drug combinations; Drug discrimination; Humans; Stimulus generalization; Triazolam

Indexed keywords

BUSPIRONE; CAFFEINE; METHYLXANTHINE; PLACEBO; TRIAZOLAM;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG DISCRIMINATION; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PSYCHOMOTOR PERFORMANCE; SELF REPORT; STIMULUS GENERALIZATION; VOLUNTEER;

ADULT; ANTI-ANXIETY AGENTS; BUSPIRONE; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DISCRIMINATION (PSYCHOLOGY); DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GENERALIZATION, STIMULUS; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PSYCHOMOTOR PERFORMANCE; TRIAZOLAM;

EID: 0030873329     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Altman JL, Albert J-M, Milstein SL and Greenberg I (1977) Drugs as discriminable events in humans. In: Discriminative Stimulus Properties of Drugs (Eds H Lal), pp. 187-206, Plenum, New York.
2. Arendt RM, Greenblatt DJ, Liebisch DC, Luu MD and Paul SM (1987) Determinants of benzodiazepine brain uptake: lipophilicity versus binding affinity. Psychopharmacology, 93, 72-76.
3. Bickel WK, Bigelow GE, Preston KL and Liebson IA (1989) Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect. Journal of Pharmacology and Experimental Therapeutics, 251, 1053-1063.
4. Bickel WK, Oliveto AH, Kamien JB, Higgins ST and Hughes JR (1993) A novel-response procedure enhances the selectivity and sensitivity of a triazolam discrimination in humans. Journal of Pharmacology and Experimental Therapeutics, 264, 360-367.
5. Boulenger J-P, Patel J and Marangos PJ (1982) Effects of caffeine and theophylline on adenosine and benzodiazepine receptors in the human brain. Neuroscience Letters, 30, 161-166.
6. Chait LD, Uhlenhuth EH and Johanson C-E (1984) An experimental paradigm for studying the discriminative stimulus properties of drugs in humans. Psychopharmacology, 82, 272-274.
7. Chait LD, Evans SM, Grant KA, Kamien JB, Johanson C-E and Schuster CR (1988) Discriminative stimulus and subjective effects of smoked marijuana in humans. Psychopharmacology, 94, 206-212.
8. Cole JO, Hecht Orzack M, Beake B, Bird M and Bar-Tal Y (1982) Assessment of the abuse liability of buspirone in recreational sedative users. Journal of Clinical Psychiatry, 43, 69-74.
9. Colpaert FC (1986) Drug discrimination: behavioral, pharmacological, and molecular mechanisms of discriminative drug effects. In: Behavioral Analysis of Drug Dependence (Eds SR Goldberg and IP Stolerman), pp. 161-193, Academic Press, NY.
10. Evans SM and Griffiths RR (1991) Dose-related caffeine discrimination in normal volunteers: individual differences in subjective effects and self-reported cues. Behavioural Pharmacology, 2, 345-356.
11. File SE, Bond AJ and Lister RG (1982) Interaction between effects of caffeine and lorazepam in performance tests and self-ratings. Journal of Clinical Psychopharmacology, 2, 102-106.
12. Griffiths RR, Evans SM, Heishman SJ, Preston KL, Sannerud CA, Wolf B and Woodson PP (1990) Low-dose caffeine discrimination in humans. Journal of Pharmacology and Experimental Therapeutics, 252, 970-978.
13. Heishman SJ and Henningfield JE (1991) Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans. Psychopharmacology, 103, 436-442.
14. Holloway FA, Modrow HE and Michaelis RC (1985) Methylxanthine discrimination in the rat: possible benzodiazepine and adenosine mechanisms. Pharmacology Biochemistry and Behavior, 22, 815-824.
15. Holtzman SG (1986) Discriminative stimulus properties of caffeine in the rat: noradrenergic mediation. Journal of Pharmacology and Experimental Therapeutics, 239, 706-714.
16. Hughes RN (1993) Effects on open-field behavior of diazepam and buspirone alone and in combination with chronic caffeine. Life Sciences, 53, 1217-1225.
17. Hughes JR, Higgins ST, Bickel WK, Hunt WK, Fenwick JW, Gulliver SB and Mirault GC (1991) Caffeine self-administration, withdrawal and adverse effects among coffee drinkers. Archives of General Psychiatry, 48, 611-617.
18. Jasinski DR (1977) Assessment of the abuse potential of morphine-like drugs (methods used in man). In: Drug Addiction I (Eds WR Martin), pp. 197-258, Springer-Verlag, NY.
19. Johanson C-E (1991a) Discriminative stimulus effects of diazepam in humans. Journal of Pharmacology and Experimental Therapeutics, 257, 634-643.
20. Johanson C-E (1991b) Further studies on the discriminative stimulus effects of diazepam in humans. Behavioural Pharmacology, 2, 357-368.
21. Kales A and Vgondzas AN (1990) Not all benzodiazepines are alike. In: Psychiatry: A World Perspective, Vol 3, (Eds CN Sefanis, AD Rabavilas and CR Soldatos), pp. 379-384, Excerpta Medica, Amsterdam.
22. Kamien JB, Bickel WK, Hughes JR, Higgins ST and Smith B (1993) Drug discrimination by humans compared to nonhumans: current status and future directions. Psychopharmacology, 111, 259-270.
23. Marangos PJ, Martino AM, Paul SM and Skolnick P (1981) The benzodiazepines and inosine antagonise caffeine-induced seizures. Psychopharmacology, 72, 269-273.
24. Martin WR, Sloan JW, Sapiro JD and Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clinical Pharmacology and Therapeutics, 12, 245-258.
25. McLeod DR, Griffiths RR, Bigelow GE and Yingling J (1982) An automated version of the digit symbol substitution test (DSST). Behavioural Research and Methodological Instruments, 14, 463-466.
26. Mohler H and Okada T (1978) Biochemical identification of the site of action of benzodiazepines in human brain by 3H-diazepam binding. Life Sciences, 22, 985-996.
27. Mumford GK and Holtzman SG (1991) Qualitative differences in the discriminative stimulus effects of low and high doses of caffeine in the rat. Journal of Pharmacology and Experimental Therapeutics, 258, 857-865.
28. Mumford GK, Evans SM, Kaminski BJ, Preston KL, Sannerud CA, Silverman K and Griffiths RR (1994) Discriminative stimulus and subjective effects of theobromine and caffeine in humans. Psychopharmacology, 115, 1-8.
29. O'Regan MH and Phillis JW (1988) Potentiation of adenosine-evoked depression of rat cerebral cortical neurons by triazolam. Brain Research, 445, 376-379.
30. Oliveto AH, Bickel WK, Hughes JR, Higgins ST and Fenwick JW (1992a) Triazolam as a discriminative stimulus in humans. Drug and Alcohol Dependence, 30, 133-144.
31. Oliveto AH, Bickel WK, Hughes JR, Shea PJ, Higgins ST and Fenwick JW (1992b) Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports. Journal of Pharmacology and Experimental Therapeutics, 261, 885-894.
32. Oliveto AH, Bickel WK, Hughes JR, Terry SY, Higgins ST and Badger GJ (1993) Pharmacological specificity of the caffeine discriminative stimulus in humans: effects of theophylline, methylphenidate and buspirone. Behavioural Pharmacology, 4, 237-246.
33. Phillis JW and Wu PH (1982) Adenosine and benzodiazepine action. In: The Pharmacology of Benzodiazepines, (Eds E Usdin, P Skolnick, JF Tallman, DJ Greenblatt, SM Paul), pp. 497-507, MacMillan Press, London.
34. Phillis JW, Wu PH and Coffin VL (1983) Inhibition of adenosine uptake into rat brain synaptosomes by prostaglandins, benzodiazepines and other centrally-active compounds. General Pharmacology, 14, 475-479.
35. Physicians Desk Reference (1988) Medical Economics Co. Inc., Oradell, NJ.
36. Polc P, Bonetti EP, Pieri L, Cumin R, Angioi RM, Mohler H and Haefely WE (1981) Caffeine antagonizes several central effects of diazepam. Life Sciences, 28, 2265-2275.
37. Preston KL, Bigelow GE, Bickel WK and Liebson IA (1987) Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline. Journal of Pharmacology and Experimental Therapeutics, 243, 1002-1009.
38. Preston KL, Bigelow GE, Bickel WK and Liebson IA (1989) Drug discrimination in human post-addicts: agonist-antagonist opioids. Journal of Pharmacology and Experimental Therapeutics, 250, 184-196.
39. Preston KL, Bigelow GE and Liebson IA (1990) Discrimination of butorphanol and nalbuphine in opioid-dependent humans. Pharmacology Biochemistry and Behavior, 37, 511-522.
40. Riblet LA, Taylor DP, Eison MS and Stanton HC (1982) Pharmacology and neurochemistry of buspirone. Journal of Clinical Psychiatry, 43, 11-16.
41. Riblet LA, Eison AS, Eison MS, Taylor DP, Temple DL and VanderMaelen CP (1984) Neuropharmacology of buspirone. Psychopathology, 17(Suppl. 3), 69-78.
42. Roache JD and Griffiths RR (1985) Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability. Journal of Pharmacology and Experimental Therapeutics, 234, 120-133.
43. Roache JD and Griffiths RR (1987) Interactions of diazepam and caffeine: behavioral and subjective dose effects in humans. Pharmacology Biochemistry and Behavior, 26, 801-812.
44. Roehrs T, Zwyghuizen-Doorenbos A, Smith D, Zorick F and Roth T (1988) Reversal by caffeine of triazolam-induced impairment of waking function. In: I. Benzodiazepine Receptor Ligands, Memory and Information Processing. Psychopharmacology Series 6, (Eds 1 Hindmarch and H Ott). pp. 194-202, Springer, Berlin, Heidelberg, New York.
45. Rush CR, Higgins ST, Hughes JR and Bickel WK (1994a) Acute behavioral effects of triazolam and caffeine, alone and in combination, in humans. Experimental and Clinical Psychopharmacology, 2, 211-222.
46. Rush CR, Higgins ST, Bickel WK and Hughes JR (1994b) Acute behavioral effects of lorazepam and caffeine, alone and in combination, in humans. Behavioural Pharmacology, 5, 245-254.
47. Schaufele P, Schumacher E, Acevedo CG and Contreras E (1995) Diazepam, adenosine analogues and calcium channel antagonists inhibit the contractile activity of the mouse urinary bladder. Archives Internationales de Pharmacodynamie et de Therapie, 329, 454-466.
48. Sellers EM, Schneiderman JK, Romach MK, Kaplan HL and Somer GR (1992) Comparative drug effects and abuse liability of lorazepam, buspirone, and secobarbital in nondependent subjects. Journal of Clinical Psychopharmacology, 12, 79-85.
49. Silverman K and Griffiths RR (1992) Low-dose caffeine discrimination and self-reported mood effects in normal volunteers. Journal of Experimental Analysis of Behavior, 57, 91-107.
50. Snyder SH and Sklar P (1984) Behavioral and molecular actions of caffeine: focus on adenosine. Journal of Psychiatric Research, 18. 91-106.
51. Taylor DP (1988) Buspirone: a new approach to the treatment of anxiety. FASEB Journal, 2, 2445-2452.
52. Winer BJ (1962) Statistical Principals in Experimental Design. McGraw-Hill Book Co. Inc., New York.
53. Winter JC (1981) Caffeine-induced stimulus control. Pharmacology Biochemistry and Behavior, 15, 157-159.